TransDigm Group Incorporated (T1DG34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 120.73 |
|---|---|
| 52-week range | 109.01 – 157.00 |
| Return, 1 month / 3 months | +4.2% / −8.6% |
| Return, 1 year / 3 years | −17.3% / +64.3% |
| Trend | Below its 200-day average |
| RSI (14) | 61 |
| Volatility (1 year) | 29.7% |
| Worst drawdown (1 year) | -29.9% |
| Average daily value traded | 0.37M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
TransDigm Group Incorporated makes engineered aerospace components and systems for aircraft. Its products include actuators, ignition systems, pumps, valves, connectors and other parts used on commercial and military aircraft. The company serves aircraft manufacturers and operators, supplying both original equipment and replacement parts for the aftermarket. It is based in Cleveland, Ohio, in the United States, and its business centres on highly engineered components for aviation platforms around the world.
TransDigm Group Incorporated is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code T1DG34, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
TransDigm Group Incorporated (T1DG34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 120.73 on 27 October 2026.
Its price-based Market X-Ray is 45 out of 100 (a weak price profile), ranking 885 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 17.3% and over the last three months it fell 8.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 28 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.9% | ||
| From 52-week high | -23.1% | ||
| Momentum | 30 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.6% | ||
| 6-month return | 4.8% | ||
| 12-month return, skipping the last month | -20.7% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.9% | ||
| Liquidity | 70 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.37M BRL | ||
| Zero-volume days | 5.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +5.6% |
|---|---|
| 1 month | +4.2% |
| 3 months | −8.6% |
| 6 months | +4.8% |
| 1 year | −17.3% |
| 3 years | +64.3% |
| 5 years | +100.0% |
Signals
| 50-day / 200-day average | 116.50 / 126.95 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.41 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Sep 2025 | USD 6.7035 |
| 3 Oct 2024 | USD 5.9915 |
| 17 Nov 2023 | USD 2.3942 |
| 18 Aug 2022 | USD 9.3281 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.